Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly, so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor and tumor neovasculature. eBAT is a bispecific angiotoxin consisting of truncated, deimmunized Pseudomonas exotoxin fused to EGF and the amino terminal fragment of urokinase. Here, we study the drug in an in vivo “ontarget” companion dog trial as eBAT effectively kills canine hemangiosarcoma and human sarcoma cells in vitro. We reasoned the model has value due to the common occurrence of spontaneous sarcomas in dogs and a limited lifespan allowing for rapid accrual and data collection. Splenectomized dogs with minimal residual disease were given one cycle of eBAT followed by adjuvant doxorubicin in an adaptive dose-finding, phase I–II study of 23 dogs with spontaneous, stage I–II, splenic hemangiosarcoma. eBAT improved 6-month survival from <40% in a comparison population to approximately 70% in dogs treated at a biologically active dose (50 μg/kg). Six dogs were long-term survivors, living >450 days. eBAT abated expected toxicity associated with EGFR targeting, a finding supported by mouse studies. Urokinase plasminogen activator receptor and EGFR are targets for human sarcomas, so thorough evaluation is crucial for validation of the dog model. Thus, we validated these markers for human sarcoma targeting in the study of 212 human and 97 canine sarcoma samples. Our results support further translation of eBAT for human patients with sarcomas and perhaps other EGFR-expressing malignancies. Mol Cancer Ther; 16(5); 956–65. ©2017 AACR.

Unlike carcinomas derived from epithelial tissues, sarcomas comprise a heterogeneous group of malignancies of mesenchymal origin (1, 2). There are 15,000 new sarcoma cases per year in the United States, consisting of 12,000 cases of soft tissue sarcoma and 3,000 cases of bone sarcomas (1). The 5-year overall survival rate is approximately 50% to 80% for sarcomas (2, 3). Development of new targeted therapies for therapy-resistant sarcoma has suffered from the lack of widely expressed mutations or overexpressed proteins that can be targeted therapeutically without risk of severe adverse events (AE; refs. 2, 4–7).

eBAT, a bispecific EGF urokinase angiotoxin, was developed as a targeted, second generation bispecific biologic drug consisting of human EGF (targeting EGFR), human amino terminal transferase [ATF; ATF is the high-affinity binding moiety of human urokinase, targeting urokinase plasminogen activator receptor (uPAR)], and genetically modified Pseudomonas exotoxin, mutated to reduce immunogenicity and facilitate endoplasmic reticulum (ER) retention. This drug was highly efficacious in the treatment of established glioma in rodent xenograft models (8). Xenograft models are informative, but targeting human cells in “nontarget” immunosuppressed mice (that do not bind human EGF and ATF) does not yield the same clinical investigative information as studies in a large animal “ontarget” models where the drug crossreacts with native EGFR and uPAR. Thus, we chose to undertake an “ontarget” clinical trial in companion dogs with hemangiosarcoma.

Canine hemangiosarcoma is a common, aggressive, incurable spontaneous sarcoma that appears to have a similar ontogenetic origin as human angiosarcoma (9, 10–12). Canine hemangiosarcoma and human angiosarcoma are both vasoformative sarcomas with similar microscopic appearance (13) that have often metastasized by the time they are diagnosed. Humans with angiosarcoma have an expected median survival of approximately 16 months (14); dogs with hemangiosarcoma have a comparable, short median survival of 4 to 6 months when treated with the standard of care of surgery and adjuvant chemotherapy (15, 16). Morbidity and mortality are usually caused by metastatic spread and/or acute internal hemorrhage secondary to tumor rupture. We hypothesized that as hemangiosarcoma is a vascular cancer, eBAT simultaneously targeting the tumor and its vasculature rendered it an excellent therapy choice.

Expression of EGFR and PLAUR/uPAR was previously characterized in human sarcomas using conventional PCR-based assays, gene expression microarrays, and IHC (17–20). In this study, we confirm such expression in a variety of human sarcomas and report on EGFR and uPAR expression on canine hemangiosarcoma.

We showed that canine hemangiosarcoma putative cancer stem cells express EGFR and uPAR and that these cells are highly sensitive to eBAT (8, 21–23). Here, we used a large “ontarget” animal study that closely parallels what could be a human clinical trial to show feasibility, safety, and efficacy of eBAT to treat sarcomas in a clinically translatable setting using spontaneous canine hemangiosarcoma as model, in both naïve disease and minimal residual disease settings. We report on the impact of bispecific targeting on the toxicity risks associated with targeting of EGFR. Our results show that eBAT is safe and potentially effective at biologically active doses despite EGFR targeting, supporting further translation for patients with sarcomas and other EGFR-expressing malignancies. Furthermore, our findings support our belief that bispecificity reduces overall toxicity risks associated with EGFR targeting.

Assessment of EGFR and PLAUR/uPAR expression in human and canine tumors

EGFR and PLAUR mRNA expression was evaluated from data for 212 human sarcomas obtained through the The Cancer Genome Atlas (TCGA) Research Network (http://cancergenome.nih.gov/). The federal project began in 2005 to catalog genetic mutations responsible for cancer using genome sequencing and bioinformatics. To perform a similar analysis in dogs, we used next-generation RNA sequencing (RNA-seq) data from canine hemangiosarcoma and canine lymphoma samples that were reported previously (24, 25). RNA-seq for 31 canine osteosarcoma samples was performed as described previously (24, 26, 27). EGFR and uPAR protein expression were evaluated in a human synovial sarcoma tissue microarray (TMA; ref. 28); the same methods were used to build a study-specific TMA that included tumors from 15 dogs as well as normal canine spleen, liver and kidney, and spleens with nodular lymphoid hyperplasia and associated hematomas as controls. A total of 97 canine sarcoma samples were analyzed (51 hemangiosarcomas and 31 osteosarcomas from independent datasets, and 15 hemangiosarcomas from dogs enrolled in our clinical study). IHC methods are provided (Supplementary Methods).

Cell lines

Hemangiosarcoma cell line Emma was derived by the Modiano laboratory in 2008 and authenticated in 2015 by the Modiano laboratory using short tandem repeat testing (DNA Diagnostic Center, Inc.). It was cultured in hemangiosarcoma medium as described previously (22, 29). Human angiosarcoma cell line AS5 was obtained from Dr. Gary K. Schwartz (Columbia University Medical Center, New York, NY) in 2013 and was cultured in hemangiosarcoma medium. Human RD rhabdomyosarcoma cell line was obtained from The Global Bioresource Center (ATCC) in January 2015. Human U2OS osteosarcoma cell line was obtained from ATCC in June 2015. Human HPB-MLT T-cell lymphoma cell line was obtained from the Cell Resource Center for Biomedical Research, Cell Bank in October 2014. These cell lines were grown in DMEM as described previously (30–32). RD, U2OS, and HPB-MLT were authenticated using STR profiles (DNA Diagnostics Center, Inc.) in 2016.

eBAT production

eBAT was produced at the University of Minnesota cGMP Molecular and Cellular Therapeutics (MCT) Facility as described previously (8). The construction of eBAT is illustrated in Fig. 1A. Release assays were done by Pace Analytical Life Sciences, LLC and/or at the MCT. Release criteria were established regarding drug purity (>95%), endotoxin (<50 Eu/mg), stability, selectivity, potency (IC50 < 1.0 nmol/L), sterility, and concentration. The drug was vialed and retested to meet critical FDA specifications.

Figure 1.

Construction and in vitro activity of eBAT: Bispecific eBAT was studied for its activity against canine and human sarcoma cells. A, Expression vector for eBAT, human EGF, and the high-affinity ATF of urokinase linked to a deimmunized PE38KDEL molecule. The fusion gene (from 5′ end to 3′ end) consisted of an NcoI restriction site, the genes for human EGF, an ATG initiation codon, the downstream 135-ATF from uPA linked by a 20 amino acid segment of human muscle aldolase (HMA), the 7 amino-acid EASGGPE linker, the first 362 amino acids of the pseudomonas exotoxin (PE) molecule with KDEL at the C terminus, and a NotI restriction site at the 3′ end of the construct. B, Canine EMMA cells were treated with various concentrations of eBAT and control CD3CD3KDEL, and then protein synthesis was measured 3 days later using a tritiated leucine uptake assay. Experimental variability is shown as triplicate samples ± SD. C, Human U-20S osteosarcoma cells were treated with various concentrations of eBAT tested against EGF4KDEL and then leucine incorporation was measured. D, Human AS5 angiosarcoma cells were treated with various concentrations of eBAT tested against CD19KDEL as negative control. Leucine incorporation was measured. E, eBAT was tested against HPB-MLT cells to test specificity. eBAT, EGF4KDEL, and 2219KDEL showed no significant cytotoxicity.

Figure 1.

Construction and in vitro activity of eBAT: Bispecific eBAT was studied for its activity against canine and human sarcoma cells. A, Expression vector for eBAT, human EGF, and the high-affinity ATF of urokinase linked to a deimmunized PE38KDEL molecule. The fusion gene (from 5′ end to 3′ end) consisted of an NcoI restriction site, the genes for human EGF, an ATG initiation codon, the downstream 135-ATF from uPA linked by a 20 amino acid segment of human muscle aldolase (HMA), the 7 amino-acid EASGGPE linker, the first 362 amino acids of the pseudomonas exotoxin (PE) molecule with KDEL at the C terminus, and a NotI restriction site at the 3′ end of the construct. B, Canine EMMA cells were treated with various concentrations of eBAT and control CD3CD3KDEL, and then protein synthesis was measured 3 days later using a tritiated leucine uptake assay. Experimental variability is shown as triplicate samples ± SD. C, Human U-20S osteosarcoma cells were treated with various concentrations of eBAT tested against EGF4KDEL and then leucine incorporation was measured. D, Human AS5 angiosarcoma cells were treated with various concentrations of eBAT tested against CD19KDEL as negative control. Leucine incorporation was measured. E, eBAT was tested against HPB-MLT cells to test specificity. eBAT, EGF4KDEL, and 2219KDEL showed no significant cytotoxicity.

Close modal

Laboratory assays

Protein synthesis assays measuring [3H]leucine incorporation were used to determine the effect of eBAT on cell lines. Briefly, cells were plated in 96-well flat-bottomed plates and allowed to adhere overnight. The targeted toxins were added in triplicate at 10-fold serial dilutions and incubated for 48 hours. Wells were then pulsed with [3H]leucine with 1 μCi per well and allowed to incubate for another 24 hours. Plates were then frozen to detach the cells, harvested onto glass fiber filters, washed, dried, and counted using standard scintillation methods. [3H]leucine assays were performed using leucine-free medium. Data are reported as the percentage of control counts.

To evaluate safety, C57BL/6 mice were administered eBAT by the intraperitoneal route twice, 2 days apart on days 1 and 3, and then were observed for AEs for 3 weeks.

Canine clinical study

Safety and efficacy of adjuvant eBAT were assessed using a Bayesian adaptive phase I–II trial design with predefined criteria of acceptable toxicity (no dose-limiting AEs) and efficacy (>50% survival at 6 months) to guide dose finding (33). eBAT was administered to dogs with spontaneous hemangiosarcoma after splenectomy and before the first of five cycles of doxorubicin chemotherapy. Eligibility was restricted to dogs with stage I or stage II splenic hemangiosarcoma with no evidence of gross metastatic disease. AEs were graded according to VCOG-CTCAE criteria (34). Survival time was measured from the date of diagnosis to the time of death and was censored at the time of last contact for dogs surviving at the time of analysis.

The clinical study, called SRCBST-1 (sarcoma bispecific toxin trial-1), was conducted with the approval of the University of Minnesota Institutional Animal Care and Use Committee (IACUC Protocols 1110A06186 and 1507-32804A). Study design and implementation conformed to Consolidated Standards of Reporting Trails (CONSORT) guidelines as they apply to studies in companion animals (35). eBAT pharmacokinetics and neutralizing antibody assays were performed for all dogs. Detailed descriptions of the comparison group, eligibility criteria and protocols for the SRCBST-1 study, pharmacokinetics, and neutralizing antibody assays are provided in the Supplementary Methods.

Data and materials availability

RNA-seq data for canine hemangiosarcoma, osteosarcoma, and lymphoma samples used for this project are available as a GEO Super Series (GSE95185).

Statistical analysis

Univariate associations between time to death and gene expression, patient characteristics, and tumor characteristics for the TCGA samples were assessed by Cox proportional hazards regression and summarized by Kaplan–Meier curves. Associations between time to death and expression of EGFR or uPAR were assessed by multivariate Cox regression analysis and adjusted for each other and for patient and tumor characteristics. Associations between EGFR and uPAR expression in human and canine tumor samples were evaluated using Pearson correlation coefficient. Cases from TCGA were censored from analysis if they had no information on survival or if they were listed as “alive” at the end of follow-up (or on the date the data were analyzed) in the TCGA database.

Dogs and disease characteristics were summarized using descriptive statistics. The biologically active dose was identified as specified by the design (33). Model-based estimates of the probability of AEs and 6-month survival were obtained from the parametric model used to guide dose finding. The probability of AEs was estimated using a logistic regression model with a linear term for dose; the probability of 6-month survival was modeled using a logistic regression model with linear and quadratic terms for dose. The probability of AEs for each dose was estimated by the sample proportion with exact confidence intervals (CI). Kaplan–Meier curves for overall survival were fit for the entire study population and only for dogs treated at the biologically active dose to obtain a nonparametric estimate of 6-month survival and median time to death. Dogs were censored if they died of causes other than hemangiosarcoma or if they were alive at the time of the analysis. Associations between AEs and baseline covariates of age, weight, and body condition score were assessed using the unpaired, two-sample t test assuming unequal variances between groups. All P values were two-sided. All analyses were performed using R version 3.0.1 (36).

eBAT kills canine and human sarcoma cells

To assess activity, eBAT was added to Emma cells, and leucine incorporation was measured as an indication of protein synthesis activity and cell viability (Fig. 1B). Emma was chosen as positive control as detectable cell surface expression of EGFR and uPAR was previously reported (22). Emma cells were killed in a dose-dependent manner, and cytotoxicity was specific as a control anti-human CD3-targeted toxin, CD3CD3KDEL, recognizing the epsilon chain of the T-cell receptor did not have activity. RD human rhabdomyosarcoma cells were also killed by eBAT in a dose-dependent manner, whereas BIC3, a recombinant anti-human CD3 immunotoxin, had no activity. The IC50 (50% inhibitory concentration for protein synthesis) for RD cells was 0.02 nmol/L. Figure 1C shows that U-2OS human osteosarcoma cells that express high levels of EGFR and uPAR were also sensitive to eBAT and interestingly, that a bispecific targeted toxin EGF4KDEL (37, 38) that simultaneously targets EGFR and the human IL4 receptor did not kill the human cell line as effectively as eBAT. The IC50 for these cell lines was in the subnanomolar range (0.06 pmol/L–0.08 nmol/L). Figure 1D shows that eBAT effectively targeted the human angiosarcoma line AS5, originating from a histologically similar tumor as canine hemangiosarcoma. eBAT was also tested against human HPB-MLT T cells, which do not express EGFR or uPAR, and it showed no significant cytotoxicity as expected (Fig. 1E). Together, these findings indicate that eBAT is extremely potent and inhibits both protein synthesis and DNA synthesis in a highly specific manner in vitro.

Human sarcomas express EGFR and urokinase receptor

The most current bioinformatics TCGA database was used to explore the expression on of EGFR and PLAUR on 212 human sarcomas (Fig. 2). Figure 2A shows that EGFR and PLAUR gene expression were detectable in 100% of samples regardless of sarcoma type with a variation in intensity. Supplementary Figure S1 shows Kaplan–Meier curves for time to death by EGFR expression for all subjects without subsetting. Subjects with EGFR expression above the median had shorter time to death than subjects with lower levels of EGFR (HR = 1.69; 95% CI, 1.02–2.81). EGFR expression showed no correlation with metastasis, age, gender, sarcoma histologic classification, or anatomic location. Figure 2B shows that PLAUR expression significantly correlated with histologic classification: levels were below the median in leiomyosarcomas, synovial sarcomas, and dedifferentiated liposarcomas, whereas they were above the median in pleomorphic malignant fibrous histiocytomas, undifferentiated pleomorphic sarcomas, and myxofibrosarcomas. Expression of EGFR was not correlated with the expression of PLAUR (R2 = 0.006). Yet, EGFR expression (P = 0.043) and PLAUR expression (P = 0.058) were both associated with time to death (Supplementary Table S1). Age, tumor volume, and presence of metastasis also were correlated with time to death.

Figure 2.

EGFR and PLAUR gene expression analysis in human sarcomas and spontaneous canine tumors. A,EGFR and PLAUR gene expression analysis was done in 212 tumor tissue samples extracted from the TCGA database. The x-axis represents the patients supervised by tumor type and the y-axis is the expression intensity as fragments per kilobase of transcript per million (FPKM) mapped reads. B, Unsupervised hierarchical cluster and heatmap highlighting EGFR and PLAUR expression in the human TCGA dataset. C, EGFR and uPAR protein expression is shown in TMAs constructed from human synovial sarcoma tissue samples. The x-axis represents patient TMAs and the y-axis represents optical density of EGFR and uPAR on IHC. D,EGFR and PLAUR gene expression analysis in an independent dataset of canine hemangiosarcoma samples. E,EGFR and PLAUR gene expression analysis in canine osteosarcoma samples. F,EGFR and PLAUR gene expression analysis in canine lymphoma samples. Tumor-bearing dogs are on the x-axis and fragments per kilobase of transcript per million mapped reads on the y-axis, illustrating the levels of EGFR and PLAUR expression from the individual tumors. The following detailed values pertain to gene expression in TCGA samples of EGFR and PLAUR, respectively: Count: 212, 212; mean (FPKM):653.4, 1,713; mean (FPKM) lower confidence limit: 548.7, 1,387; mean (FPKM) upper confidence limit: 758.0, 2,040; variance: 600,273, 5,844,287; SD: 774.8, 2,418; mean SE: 53.1, 165; coefficient of variation: 1.2, 1.4; minimum (FPKM): 3.1, 40.9; minimum (FPKM): 6,575.1, 19,171.7; median (FPKM): 410.0, 757.9; median error: 4.56, 14.2; percentile 25% (Q1): 215.4, 250.4; percentile 75% (Q3): 752.9, 2,149.

Figure 2.

EGFR and PLAUR gene expression analysis in human sarcomas and spontaneous canine tumors. A,EGFR and PLAUR gene expression analysis was done in 212 tumor tissue samples extracted from the TCGA database. The x-axis represents the patients supervised by tumor type and the y-axis is the expression intensity as fragments per kilobase of transcript per million (FPKM) mapped reads. B, Unsupervised hierarchical cluster and heatmap highlighting EGFR and PLAUR expression in the human TCGA dataset. C, EGFR and uPAR protein expression is shown in TMAs constructed from human synovial sarcoma tissue samples. The x-axis represents patient TMAs and the y-axis represents optical density of EGFR and uPAR on IHC. D,EGFR and PLAUR gene expression analysis in an independent dataset of canine hemangiosarcoma samples. E,EGFR and PLAUR gene expression analysis in canine osteosarcoma samples. F,EGFR and PLAUR gene expression analysis in canine lymphoma samples. Tumor-bearing dogs are on the x-axis and fragments per kilobase of transcript per million mapped reads on the y-axis, illustrating the levels of EGFR and PLAUR expression from the individual tumors. The following detailed values pertain to gene expression in TCGA samples of EGFR and PLAUR, respectively: Count: 212, 212; mean (FPKM):653.4, 1,713; mean (FPKM) lower confidence limit: 548.7, 1,387; mean (FPKM) upper confidence limit: 758.0, 2,040; variance: 600,273, 5,844,287; SD: 774.8, 2,418; mean SE: 53.1, 165; coefficient of variation: 1.2, 1.4; minimum (FPKM): 3.1, 40.9; minimum (FPKM): 6,575.1, 19,171.7; median (FPKM): 410.0, 757.9; median error: 4.56, 14.2; percentile 25% (Q1): 215.4, 250.4; percentile 75% (Q3): 752.9, 2,149.

Close modal

Figure 2C shows expression of EGFR and uPAR proteins in human synovial sarcoma TMA. Both proteins were detectable in each of the 54 synovial sarcomas. Supplementary Table S2 shows more detailed characteristics of these patients and treatments. Neither gene was associated with survival when assessed independently, together, or with other covariates (Supplementary Table S3).

Expression of EGFR and urokinase receptor is conserved in canine hemangiosarcomas

To thoroughly evaluate EGFR and PLAUR expression in canine sarcomas, we evaluated mRNA expression in an independent dataset of 51 canine hemangiosarcomas by RNA-seq (24) and two additional datasets consisting of 31 canine osteosarcomas and 29 canine lymphoma tissue samples (Fig. 2D–F; ref. 25). Results were similar to those in human sarcomas: expression of both EGFR and PLAUR genes was detectable in all canine sarcomas, with hemangiosarcoma having higher levels of PLAUR mRNA, and hemangiosarcoma and osteosarcomas having approximately equivalent levels of EGFR mRNA. As expected, expression of both genes was significantly lower (P < 2 × 10−5) in canine lymphoma samples as compared with canine sarcomas (Fig. 2F).

eBAT is safe and potentially effective in dogs with spontaneous hemangiosarcoma in a clinical setting

Hemangiosarcoma was chosen as a target disease based on its extremely poor prognosis in dogs. Immunostaining of tumor tissues from 15 dogs enrolled in the SRCBST-1 study confirmed that both eBAT targets were expressed at the protein level in all dogs examined replicating the results of immunohistochemical studies in the human synovial sarcoma TMA where both proteins were expressed almost exclusively by tumor cells. Figure 3 shows representative photomicrographs of EGFR and uPAR staining in the canine and human TMAs. Expression of both proteins was variable in nonmalignant tissues. Supplementary Figure S2 shows graphical data summaries.

Figure 3.

EGFR and uPAR expression in human synovial sarcomas and canine hemangiosarcoma TMA from 15 dogs in the SRCBST study. Synovial cell sarcoma TMA spots immunohistochemically stained for EGFR and uPAR. Representative highly and lowly stained spots for EGFR are shown (A and B, human; C and D, canine). Representative highly and lowly stained spots for uPAR are shown (E and F, human; G and H, canine). An example of heterogeneous expression of uPAR is shown in the human synovial TMA where uPAR expression is much higher in the glandular cells staining dark brown and forming elongated glands, sometimes with compressed slit-like spaces between the gland cells (I). An admixture of spindled and glandular cells imparting a marbled-like appearance is also shown (J).

Figure 3.

EGFR and uPAR expression in human synovial sarcomas and canine hemangiosarcoma TMA from 15 dogs in the SRCBST study. Synovial cell sarcoma TMA spots immunohistochemically stained for EGFR and uPAR. Representative highly and lowly stained spots for EGFR are shown (A and B, human; C and D, canine). Representative highly and lowly stained spots for uPAR are shown (E and F, human; G and H, canine). An example of heterogeneous expression of uPAR is shown in the human synovial TMA where uPAR expression is much higher in the glandular cells staining dark brown and forming elongated glands, sometimes with compressed slit-like spaces between the gland cells (I). An admixture of spindled and glandular cells imparting a marbled-like appearance is also shown (J).

Close modal

Table 1A summarizes baseline characteristics for all dogs by dose, and Table 1B illustrates a treatment timeline for the canine study. The first dog accepted into the study was determined to have metastatic lesions to its liver upon enrolment in the trial, but it was decided to continue treatment and report results as part of the study. A CONSORT diagram showing the flow of study participants is provided in Supplementary Fig. S3.

Table 1.

Demographic data for canine subjects and experimental treatment schedule

VariableLevel/unitAll dogsDose 1Dose 2Dose 3ControlPaPb
A. Baseline characteristics for all dogs and by dose summarized by N (%) or mean (SD) 
Age Years 9.4 (1.7) 9.2 (1.6) 9.5 (1.8) 8.6 (1.7) 10.5 (2.2) 0.054 0.135 
Sex 11 (47.8) 1 (33.3) 9 (52.9) 1 (33.3) 13 (46.4) 0.763 
 12 (52.2) 2 (66.7) 8 (47.1) 2 (66.7) 15 (53.6)   
BCS  5.7 (1) 5.7 (0.6) 5.5 (1.1) 6.3 (0.6) 5.2 (1)c 0.159 0.385 
Hemoabdomen 20 (87) 2 (66.7) 15 (88.2) 3 (100) 22 (78.6) 0.487 0.69 
 3 (13) 1 (33.3) 2 (11.8) 0 (0) 6 (21.4)   
Stage 2 (8.7) 0 (0) 2 (11.8) 0 (0) 5 (17.9)   
 II 20 (87) 2 (66.7) 15 (88.2) 3 (100) 23 (82.1)   
 III 1 (4.3) 1 (33.3) 0 (0) 0 (0) 0 (0) 0.324 0.693 
Time from surgery to treatment Days 22.9 (10.9) 15 (5.2) 25.2 (11.7) 18 (2)    
Weight kg 24.6 (11.7) 30.1 (4.6) 22.1 (12.1) 33.3 (9.1) 27.1 (11.3) 0.445 0.178 
Time to initiation of chemotherapy Days 43.7 (11.3) 35.3 (5.5) 46.2 (12.2) 38.7 (3.1) 20.8 (6.5) 
Doxorubicin Doses 4.3 (1.4) 4.3 (1.2) 4.4 (1.5) 4 (1.7) 4.1 (1.2) 0.669 0.628 
B. Study protocol timeline 
Splenectomy   eBAT eBAT eBAT Recheck Doxorubicin Recheck, doxorubicin 
↓   ↓ ↓ ↓ ↓ ↓ ↓ 
-10-0   21 22-180 
↑   ↑ ↑ ↑ ↑ ↑ ↑ 
Blood UA PE, staging   Blood PK, NA PE Blood PE Blood PK PE Blood NA PE Blood NA PE Blood Staging PE 
VariableLevel/unitAll dogsDose 1Dose 2Dose 3ControlPaPb
A. Baseline characteristics for all dogs and by dose summarized by N (%) or mean (SD) 
Age Years 9.4 (1.7) 9.2 (1.6) 9.5 (1.8) 8.6 (1.7) 10.5 (2.2) 0.054 0.135 
Sex 11 (47.8) 1 (33.3) 9 (52.9) 1 (33.3) 13 (46.4) 0.763 
 12 (52.2) 2 (66.7) 8 (47.1) 2 (66.7) 15 (53.6)   
BCS  5.7 (1) 5.7 (0.6) 5.5 (1.1) 6.3 (0.6) 5.2 (1)c 0.159 0.385 
Hemoabdomen 20 (87) 2 (66.7) 15 (88.2) 3 (100) 22 (78.6) 0.487 0.69 
 3 (13) 1 (33.3) 2 (11.8) 0 (0) 6 (21.4)   
Stage 2 (8.7) 0 (0) 2 (11.8) 0 (0) 5 (17.9)   
 II 20 (87) 2 (66.7) 15 (88.2) 3 (100) 23 (82.1)   
 III 1 (4.3) 1 (33.3) 0 (0) 0 (0) 0 (0) 0.324 0.693 
Time from surgery to treatment Days 22.9 (10.9) 15 (5.2) 25.2 (11.7) 18 (2)    
Weight kg 24.6 (11.7) 30.1 (4.6) 22.1 (12.1) 33.3 (9.1) 27.1 (11.3) 0.445 0.178 
Time to initiation of chemotherapy Days 43.7 (11.3) 35.3 (5.5) 46.2 (12.2) 38.7 (3.1) 20.8 (6.5) 
Doxorubicin Doses 4.3 (1.4) 4.3 (1.2) 4.4 (1.5) 4 (1.7) 4.1 (1.2) 0.669 0.628 
B. Study protocol timeline 
Splenectomy   eBAT eBAT eBAT Recheck Doxorubicin Recheck, doxorubicin 
↓   ↓ ↓ ↓ ↓ ↓ ↓ 
-10-0   21 22-180 
↑   ↑ ↑ ↑ ↑ ↑ ↑ 
Blood UA PE, staging   Blood PK, NA PE Blood PE Blood PK PE Blood NA PE Blood NA PE Blood Staging PE 

NOTE: Blood: complete blood count, serum biochemical profile, prothrombin time, partial thromboplastin time; doxorubicin: Adriamycin chemotherapy (30 mg/m2) intravenously every 3 weeks.

Abbreviations: BCS, body condition score; eBAT, EGF-bispecific angiotoxin; PE, physical examination; PK, pharmacokinetics; UA, urinalysis.

aP value for comparison group versus all dogs.

bP value for comparison group versus dose level 2.

cBCS was missing for 2 control dogs. Four breeds enrolled in the study included 5 Labrador retrievers, 3 mixed breed, 2 English springer spaniels, and 1 each English setter, Brittany Spaniel, Airedale Terrier, Bichon Frise, Newfoundland, Vizsla, Goldendoodle, Cairn Terrier, Papillon, Dachshund, Golden Retriever, Rat Terrier, and German Shepherd Dog.

eBAT was safe and well tolerated in all dogs. When dog #23 reached the 6-month milestone, interim analysis showed that the study had reached stability at the biologically active dose of 50 μg/kg (dose level 2 in the escalation scheme) and was unlikely to change with additional subjects so enrolment was stopped. On the basis of the favorable trade-off between efficacy and toxicity observed at 50 μg/kg, this dose was identified as the biologically active dose and was used for all subsequent cohorts.

Median survival for the 23 dogs treated with adjuvant eBAT (eBAT group) was 8.1 months (Fig. 4A) compared with 4.9 months for the comparison group of dogs treated with standard of care alone. Median survival was 8.6 months for the 17 dogs treated at the biologically active dose (Fig. 4B). Overall, 6-month survival rates were 65.2%, and 70.6%, and 38.7%, for the eBAT group, the group treated at the biologically active dose, and the comparison group, respectively.

Figure 4.

Effect of eBAT on survival of dogs with splenic hemangiosarcoma treated with adjuvant doxorubicin chemotherapy. A, Kaplan–Meier curve for all 23 dogs in the SRCBST-1 study versus the comparison dogs. B, Kaplan–Meier curve for the 17 dogs treated at the biologically active dose versus the comparison dogs. Curves illustrate prolongation of survival in dogs treated with eBAT compared with the comparison group.

Figure 4.

Effect of eBAT on survival of dogs with splenic hemangiosarcoma treated with adjuvant doxorubicin chemotherapy. A, Kaplan–Meier curve for all 23 dogs in the SRCBST-1 study versus the comparison dogs. B, Kaplan–Meier curve for the 17 dogs treated at the biologically active dose versus the comparison dogs. Curves illustrate prolongation of survival in dogs treated with eBAT compared with the comparison group.

Close modal

Average time from splenectomy to initiation of chemotherapy was shorter in the comparison group (20.8 days) than in the eBAT group (43.7 days) or the group treated at the biologically active dose (46.2 days). Six (26%) of 23 dogs and 5 of 17 (29%) treated at the biologically active dose (dose level 2) survived one year; all 6 dogs surviving one year had survival of at least 450 days, and 2 dogs are still alive at 1,245 and 963 days. Detectable levels of eBAT were achieved in the systemic circulation of dogs treated by intravenous infusion (not shown).

eBAT shows limited toxicity in vivo

For our companion canine study, the estimated probabilities of AEs by dose are shown in Table 2A, and specific information regarding AEs is shown in Table 2B. No AEs were observed at 25 μg/kg (dose level 1). Reversible liver toxicity was noted in 2 dogs treated at dose level 2, reversible hypotensive events were observed in 2 dogs treated at dose level 2, and two dogs treated at dose level 3. Grade 1–3 toxicities associated with subsequent doxorubicin chemotherapy were predictable and limited to 12 dogs in total. No dogs experienced cutaneous, ocular, gastrointestinal toxicity, or laboratory abnormalities that have been previously associated with EGFR-targeted therapies in humans (6). Necropsy was performed in 2 of 23 dogs and showed no evidence of chronic changes attributable to eBAT. Both of these dogs died due to progressive hemangiosarcoma.

Table 2.

AEs for dogs in the SRCBST study and mice treated with eBAT

A. Summary of AEs, including the empirical and model-based estimated rate by treatment group
Dose levelNAEsaAE rate – empirical (95% CI)AE Rate – from model (95% CI)
1 (25 μg/kg) 0 (0–70.8) 10.1 (0.3–31.9)  
2 (50 μg/kg) 17 17.6 (3.8–43.4) 19.5 (6.6–37.7)  
3 (100 μg/kg) 66.7 (9.4–99.2) 44.4 (10.3–90.6)  
B. Description of AEs in individual dogs, management, and outcome 
Dog ID and breed Dose level AEs Management Outcome  
MNb 11 Grade 3 ALT elevation after 1st infusion Second eBAT infusion delayed one week Full recovery  
Cairn Terrier  Hypotensive eventc during 2nd infusion IV fluid bolus 3rd eBAT infusion not administered Full recovery  
MN 17 Labrador retriever Hypotensive event followed by a seizure during 1st infusion IV fluid bolus, infusion restated 45 minutes later with no complications Full recovery  
MN 22 Rat terrier Grade 2 ALT elevation after 1st infusion Monitoring Full recovery  
MN 07 Newfoundland Hypotensive event at the end of 3rd infusion IV fluid bolus Full recovery  
MN 09 Goldendoodle Hypotensive event during 2nd infusion IV fluid bolus, infusion not restarted Full recovery  
C. Summary of death events in normal mice treated with ligand-specific toxins 
 Observed deaths (%) 
Treatment Dose (μg/kg) 
 10 20 40 80 160 
Monospecific EGF toxin 0/8 (0) 2/8 (25) 6/8 (75) 8/8 (100) 8/8 (100) 
Monospecific uPA toxin 0/8 (0) 0/8 (0) 2/8 (25) 8/8 (100) 8/8 (100) 
Monospecific EGF toxin + monospecific uPA toxin 0/7 (0) 1/7 (14) 2/7 (29) 7/7 (100) 7/7 (100) 
eBAT 0/8 (0) 0/8 (0) 0/8 (0) 0/8 (0) 0/8 (0) 
A. Summary of AEs, including the empirical and model-based estimated rate by treatment group
Dose levelNAEsaAE rate – empirical (95% CI)AE Rate – from model (95% CI)
1 (25 μg/kg) 0 (0–70.8) 10.1 (0.3–31.9)  
2 (50 μg/kg) 17 17.6 (3.8–43.4) 19.5 (6.6–37.7)  
3 (100 μg/kg) 66.7 (9.4–99.2) 44.4 (10.3–90.6)  
B. Description of AEs in individual dogs, management, and outcome 
Dog ID and breed Dose level AEs Management Outcome  
MNb 11 Grade 3 ALT elevation after 1st infusion Second eBAT infusion delayed one week Full recovery  
Cairn Terrier  Hypotensive eventc during 2nd infusion IV fluid bolus 3rd eBAT infusion not administered Full recovery  
MN 17 Labrador retriever Hypotensive event followed by a seizure during 1st infusion IV fluid bolus, infusion restated 45 minutes later with no complications Full recovery  
MN 22 Rat terrier Grade 2 ALT elevation after 1st infusion Monitoring Full recovery  
MN 07 Newfoundland Hypotensive event at the end of 3rd infusion IV fluid bolus Full recovery  
MN 09 Goldendoodle Hypotensive event during 2nd infusion IV fluid bolus, infusion not restarted Full recovery  
C. Summary of death events in normal mice treated with ligand-specific toxins 
 Observed deaths (%) 
Treatment Dose (μg/kg) 
 10 20 40 80 160 
Monospecific EGF toxin 0/8 (0) 2/8 (25) 6/8 (75) 8/8 (100) 8/8 (100) 
Monospecific uPA toxin 0/8 (0) 0/8 (0) 2/8 (25) 8/8 (100) 8/8 (100) 
Monospecific EGF toxin + monospecific uPA toxin 0/7 (0) 1/7 (14) 2/7 (29) 7/7 (100) 7/7 (100) 
eBAT 0/8 (0) 0/8 (0) 0/8 (0) 0/8 (0) 0/8 (0) 

NOTE: Groups of 8 C57BL/6 mice were administered monospecific EGF toxin, monospecific uPA toxin, monospecific EGF toxin and monospecific uPA toxin, and eBAT intraperitoneally twice, 2 days apart, on days 1 and 3 and were subsequently monitored for the occurrence of AEs for 3 weeks.

Abbreviation: CI, confidence interval.

aTotal count of dogs experiencing AEs (not total number of AEs).

bMN = Minnesota (institutional assignment); dogs were coded using MN followed by a number assigned sequentially based on order of enrollment.

cHypotensive events noted in 4 dogs were characterized by mean arterial pressure <60 mm Hg, hind limb weakness, pale mucous membranes, weak femoral pulses, and a single vomiting episode in one dog. All other dogs had no AEs.

As other studies have shown that EGFR-targeted therapies are associated with significant dose-limiting cutaneous and gastrointestinal toxicities (6, 7), we further examined the safety of eBAT versus EGF toxin alone in normal C57BL/6 mice. MTDs were established for monospecific EGF toxin given alone (20 μg/kg), monospecific uPA toxin given alone (40 μg/kg), and both drugs were administered jointly (40 μg/kg); most deaths occurred within 7 days posttreatment. There were no deaths or gross toxicities in mice receiving up to 160 μg/kg of eBAT (Table 2C).

Anti-eBAT antibody responses are sporadic and do not interfere with outcome

eBAT contains a bacterial toxin, so immunogenicity was expected and considered as a potential barrier to bioactivity. Samples for neutralizing antibody (NA) measurement were available for all dogs at baseline, 19 of 23 dogs on day 8, and 7 of 23 dogs on day 21.

Dogs in which we could detect drug in the circulation on day 1 had significantly better survival (P = 0.002) than dogs in which drug was undetectable (404 days vs. 172 days; HR = 0.20; 95% CI, 0.07–0.63). Drug was detectable on day 1 in 4 of 9 dogs with no evidence of antibody at baseline or following eBAT administration, 7 of 8 dogs with antibody formation after eBAT treatment, and 1 of 4 dogs with preexisting antibody (this dog was treated at the highest dose). No associations were found between survival and detectable drug at days 5 or 6 (P = 0.542), AUC at day 1 (P = 0.96), AUC at day 5 or 6 (P = 0.82), or the presence of neutralizing antibodies (P = 0.654).

The major contributions of this study were the following: (i) first-time evaluation of a potent bispecific, antiangiogenic targeted toxin in an “ontarget” large animal sarcoma model demonstrating potential antisarcoma activity and long-term survival; (ii) description of an EGFR-targeted therapy that is surprisingly well tolerated; and (iii) findings supporting our belief that bispecific targeting reduces toxicity risks associated with EGFR targeting.

We tested eBAT in a model of canine hemangiosarcoma using an adaptive study design in the minimal residual disease setting. We identified a biologically active dose that was safe and potentially effective. The cause of the reversible hypotensive events noted in 4 dogs remains unclear. Hypotension was reported in a previous study investigating treatment of advanced solid tumors with immunotoxin LMB-1, occurring in some patients treated at doses greater than 75 μg/kg. Similar to our findings, these events were transient and did not require fluids or pressor agents (39). None of the treated dogs experienced signs of capillary leak syndrome, the toxicity of greatest concern for immunotoxins (40, 41). Furthermore, the lack of AEs similar to those caused by EGFR-targeted therapies (6, 7) suggests that the addition of the uPAR-directed ligand enhances targeting specificity to tumors, leading to diminished toxicity, consistent with our mouse data. However, we are aware that humans are physiologically different and may provide a greater challenge.

Bispecificity is one unique aspect of eBAT, as this may permit reactivity with a wider range of cell surface markers, enhancing the ability to kill resistant tumor cell outliers. In the case of eBAT, studies showed an ability to simultaneously target uPAR on human vascular endothelial cells (HUVEC cells) and EGFR on tumor cells (8). We believe that bispecificity contributed to the notable clinical effect. Our results are further strengthened by the design that allowed dose finding to be guided by safety and 6-month survival (33), in turn allowing us to identify a biologically active dose without having to establish a MTD. Dog owners participating in companion dog studies do not abide unnecessary pet mortality risk. That being said, the data suggest the biologically active dose is lower than the MTD. The favorable clinical results could be also due to testing of the drug in the minimal residual disease setting, which is a unique opportunity afforded by the canine model and is in contrast to other studies of immunotoxins in humans, where bulky, refractory, heavily pretreated tumor loads exceed the capabilities of the test article. Canine hemangiosarcoma provided a setting where we could test eBAT on a targetable disease with a high probability of detecting an efficacy signal in addition to evaluating safety. This was not done with the single intent to develop a treatment specifically for hemangio/angiosarcomas, but rather provide a proof of concept to inform and optimize the design of future clinical trials in humans with a variety of targetable cancers.

Six of 7 dogs had NAs on day 21, suggesting that the use of a deimmunized toxin was justified (42). Nonetheless, the presence of NAs was not associated with survival outcomes, and there was no correlation between NAs and the dose of eBAT received or the drug pharmacokinetics. These findings were similar to other studies with targeted toxin where antitoxin antibody titers did not correlate with antitumor activity (43). Our results exceeded expectations for outcome of dogs with stage I or stage II hemangiosarcoma based on our historical data and on other published data from comparable populations treated with the standard of care (44, 45). In fact, dogs receiving eBAT had longer survival times than dogs treated with any other contemporary experimental therapy (44–47). The most recent detection of an efficacy signal in the treatment of canine hemangiosarcoma prior to our study dates back to 1995 when liposome-encapsulated muramyl tripeptide phosphatidylethanolamine was used as an adjuvant to standard-of-care therapy (48). The 1-year survival for dogs treated with eBAT at the biologically active dose was almost 40%, and the proportion of dogs living 6 months or longer nearly doubled compared with our comparison population. Six dogs were considered long-term survivors, having lived more than 450 days.

It is intriguing that time to initiation of chemotherapy was longer in dogs treated with eBAT than in the comparison group. It is generally assumed that a shorter time to initiation of chemotherapy would produce more favorable outcomes, but survival was longer in dogs treated with eBAT even though chemotherapy was delayed. It is unlikely that the variability in chemotherapy protocols used in the comparison group had an impact on survival as, historically, single-agent doxorubicin and combination protocols are equally effective (44, 45). Furthermore, we found no significant difference between the number of doxorubicin doses in the comparison group versus all dogs receiving eBAT or dogs treated at the biologically active dose. The use of a comparison group enabled us to implement a novel adaptive clinical trial design and identify an efficacy signal of eBAT, but it is important to acknowledge the potential bias associated with the lack of a contemporary control group with blinding and randomization, which would more accurately predict efficacy. Our dosing and dose schedule was chosen partly on the basis of a previous study by our group in humans with an anti-B-cell cancer targeted toxin (40), and partly on laboratory animal safety data. Still, metastatic disease occurred in about half of the dogs in this eBAT study. Pharmacokinetic studies show that eBAT is metabolized quickly within a few hours. We intend to use this information to optimize dose schedule in the future. Repeat cycles could prolong remissions as has been shown in studies with targeted Pseudomonas exotoxin in humans (40, 49), retreatment at relapse could prolong survival, and even the delivery methods could be improved.

The mechanism of action of eBAT remains to be fully elucidated. In this study, both eBAT targets were expressed in human sarcoma samples. Thus, our findings from the TCGA and from the synovial sarcoma TMA analysis support other reports in the literature (17–20) regarding EGFR and PLAUR expression. A recent study confirmed that uPAR was expressed in 100% (57/57) of canine hemangiosarcomas tested, but only in 30% (8/26) of hemangioma samples (50). Here, we demonstrated expression of both targets in canine hemangiosarcoma samples and expression was present in the tumor cells and/or in the tumor microenvironment, but they also were present in normal tissues. Taken together, our expression data indicate that these markers are excellent targets, and eBAT may be highly effective in sarcoma intervention. Furthermore, our data suggest that the excellent safety profile could be due to a unique reactivity with tumor cells, although it also could be due to the extremely low dose required to control or ablate the mass of malignant cells present in the minimal residual disease setting. However, we cannot exclude the possibility that eBAT makes the microenvironment inhospitable for tumor formation. The apparent high expression of uPAR in tumor-associated mononuclear inflammatory cells, in addition to tumor cells, also raises the possibility that eBAT acts through a primary immune mechanism by eliminating or attenuating this cellular compartment, which in turn removes a strong impetus for tumor formation and/or tumor progression (24, 51, 52). The fact that EGF4KDEL was not as effective as EGFATFKDEL (eBAT) in vitro suggests that simultaneously targeting EGFR and uPAR may be essential for optimal efficacy of this drug. Further studies are needed to understand how the bispecific nature of eBAT confers enhanced specificity even in an “ontarget” animal model. Future imaging studies in companion animal models and humans will be required to elucidate the biodistribution of eBAT and identify sites of accumulation in tumor and nontumor areas.

In conclusion, we demonstrated that eBAT is safe and that the addition of a uPAR-directed ligand to the EGFR-targeting molecule abrogated the dose-limiting cutaneous, ocular, and gastrointestinal toxicities, or hypomagnesemia generally associated with EGFR targeting. We also showed that eBAT has biological activity in a highly metastatic, incurable canine sarcoma that carries many similarities with its human counterpart. In fact, in vitro testing of eBAT on the human angiosarcoma cell line AS5 showed that the drug was selective and highly effective. The strategy is not aimed at modulating EGF or uPA-dependent pathways, as neither EGFR nor uPAR appear to act as drivers of tumor progression. Rather the proteins act as “bait” for a ligand-targeted cytotoxic therapy. Given that the targets are invariably expressed in human sarcomas, our data provide a strong rationale for translation of eBAT in the treatment of human sarcomas and potentially other EGFR and uPAR-expressing tumors.

A. Borgatti has ownership interest (including patents) in a patent entitled "Reduction of EGFR therapeutic toxicity" filed by the University of Minnesota Office of Technology Commercialization. J.F. Modiano has ownership interest (including patents) in US Patent Application 15/280,673. D.A. Vallera has ownership interest (including patents) in a patent entitled "Reduction of EGFR therapeutic toxicity" filed by the University of Minnesota Office of Technology Commercialization. No potential conflicts of interest were disclosed by the other authors.

Conception and design: A. Borgatti, J.S. Koopmeiners, J. Froelich, M.S. Henson, K. Pilbeam, J.F. Modiano, D.A. Vallera

Development of methodology: A. Borgatti, A.E. Rizzardi, C.L. Forster, J. Froelich, J.F. Modiano

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Borgatti, A.L. Winter, K. Stuebner, D. Todhunter, A.E. Rizzardi, J.C. Henriksen, S. Schmechel, J.-H. Kim, J. Froelich, J. Walz, M.S. Henson, J.F. Modiano

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. Borgatti, J.S. Koopmeiners, A.L. Sarver, S. Schmechel, J.-H. Kim, J. Froelich, F. Oh, J.F. Modiano

Writing, review, and/or revision of the manuscript: A. Borgatti, J.S. Koopmeiners, A.L. Winter, K. Stuebner, S. Schmechel, J. Froelich, J. Walz, M.S. Henson, M. Breen, J.F. Modiano, D.A. Vallera

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A. Borgatti, A.L. Winter, K. Stuebner, D. Todhunter, A.E. Rizzardi, J.C. Henriksen, J. Froelich, J. Walz, K. Lindblad-Toh, J.F. Modiano

Study supervision: A. Borgatti, K. Stuebner, J.F. Modiano, D.A. Vallera

Other (responsible for obtaining funding): J.F. Modiano

We thank Dr. Brenda Weigel for helpful discussions, Elizabeth Taras for laboratory assistance, Dr. David Largaespada and his laboratory for providing the synovial sarcoma TMAs, Dr. Gary K. Schwartz, Columbia University Medical Center, for generously providing the AS5 human angiosarcoma cell line, Drs. M. Gerard O’Sullivan, Ingrid Cornax, Ramesh Kovi, and Jill Schappa for assistance with pathologic analyses, Mitzi Lewellen for sample archiving and management, Alpay Temiz and Milcah Scott for their assistance in managing the data and depositing them in GEO, the oncology clinicians and staff of the University of Minnesota Veterinary Medical Center for assistance with management of dogs participating in the study, and importantly, clients who allowed their pets to enroll in the study, and the dogs who made the study possible.

This work was supported by grant K01OD017242 (A. Borgatti) from the Office of The Director, NIH, grant AB15MN-002 from the National Canine Cancer Foundation (to A. Borgatti), a grant from the Masonic Cancer Center, University of Minnesota Sarcoma Translational Working Group (to J.F. Modiano, D.A. Vallera, A. Borgatti, and J.S. Koopmeiners), grant 1889-G from the AKC Canine Health Foundation (to J.F. Modiano, M. Breen, and K. Lindblad-Toh), the U.S. Public Health Service Grant R01 CA36725 awarded by the NCI and the NIAID, DHHS (to D.A. Vallera), the Randy Shaver Cancer Research and Community Foundation (to D.A. Vallera), Hyundai Scholar Senior Research Award, Hyundai Hope on Wheels (to D.A. Vallera), a CETI Translational Award from the University of Minnesota Masonic Cancer Center (to D. Vallera), and a grant from GREYlong (to J.F. Modiano). The NIH Comprehensive Cancer Center Support Grant to the Masonic Cancer Center (P30 CA077598) provided support for bioinformatics and comparative pathology services. The NIH Clinical and Translational Science Award to the University of Minnesota (UL1 TR000114) provided support for immunohistology services. RNA sequencing for osteosarcoma samples was supported by the Sobiech Osteosarcoma Fund Award from the Children's Cancer Research Fund. The authors gratefully acknowledge generous support from the Angiosarcoma Awareness Foundation and donations to the Animal Cancer Care and Research Program of the University of Minnesota that helped support this project. J.F. Modiano is supported in part by the Alvin S. and June Perlman Chair in Animal Oncology at the University of Minnesota.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Cassier
PA
,
Polivka
V
,
Judson
I
,
Soria
JC
,
Penel
N
,
Marsoni
S
, et al
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database
.
Ann Oncol
2014
;
25
:
1222
8
.
2.
Linch
M
,
Miah
AB
,
Thway
K
,
Judson
IR
,
Benson
C
. 
Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies
.
Nat Rev Clin Oncol
2014
;
11
:
187
202
.
3.
Ng
VY
,
Scharschmidt
TJ
,
Mayerson
JL
,
Fisher
JL
. 
Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions
.
Anticancer Res
2013
;
33
:
2597
604
.
4.
Borden
EC
,
Baker
LH
,
Bell
RS
,
Bramwell
V
,
Demetri
VGD
,
Eisenberg
BL
, et al
Soft tissue sarcomas of adults: state of the translational science
.
Clin Cancer Res
2003
;
9
:
1941
56
5.
Frith
AE
,
Hirbe
AC
,
Van Tine
BA
. 
Novel pathways and molecular targets for the treatment of sarcoma
.
Curr Oncol Rep
2013
;
15
:
378
85
.
6.
Funakoshi
T
,
Latif
A
,
Galsky
MD
. 
Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials
.
Cancer Treat Rev
2014
;
40
:
636
47
.
7.
Launay-Vacher
V
,
Aapro
M
,
De Castro
G
 Jr
,
Cohen
E
,
Deray
G
,
Dooley
M
, et al
Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)
.
Ann Oncol
2015
;
26
:
1677
84
.
8.
Tsai
AK
,
Oh
S
,
Chen
H
,
Shu
Y
,
Ohlfest
JR
,
Vallera
DA
. 
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature
.
J Neurooncol
2011
;
103
:
255
66
.
9.
Fosmire
SP
,
Dickerson
EB
,
Scott
AM
,
Bianco
SR
,
Pettengill
MJ
,
Meylemans
H
, et al
Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium
.
Lab Invest
2004
;
84
:
562
72
.
10.
Kim
JH
,
Graef
AJ
,
Dickerson
EB
,
Modiano
JF
. 
Pathobiology of hemangiosarcoma in dogs: research advances and future perspectives
.
Vet Sci
2015
;
2
:
388
405
.
11.
Lamerato-Kozicki
AR
,
Helm
KM
,
Jubala
CM
,
Cutter
GC
,
Modiano
JF
. 
Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation
.
Exp Hematol
2006
;
34
:
870
8
.
12.
Liu
L
,
Kakiuchi-Kiyota
S
,
Arnold
LL
,
Johansson
SL
,
Wert
D
,
Cohen
SM
. 
Pathogenesis of human hemangiosarcomas and hemangiomas
.
Human Pathol
2013
;
44
:
2302
11
.
13.
Andersen
NJ
,
Froman
RE
,
Kitchell
BE
,
Duesbery
NS
. 
Clinical and molecular biology of angiosarcoma
. In:
Derbel
PF
,
editor
.
Soft tissue tumors
.
Rijeka
,
Croatia
:
InTech
; 
2011
.
14.
Buehler
D
,
Rice
SR
,
Moody
JS
,
Rush
P
,
Hafez
GR
,
Attia
S
, et al
Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience
.
Am J Clin Oncol
2014
;
37
:
473
9
.
15.
Wendelburg
KM
,
Price
LL
,
Burgess
KE
,
Lyons
JA
,
Lew
FH
,
Berg
J
. 
Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001–2012)
.
J Am Vet Med Assoc
2015
;
247
:
393
403
.
16.
Gardner
HL
,
London
CA
,
Portela
RA
,
Nguyen
S
,
Rosenberg
MP
,
Klein
MK
, et al
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma
.
BMC Vet Res
2015
;
11
:
131
.
17.
Albritton
KH
,
Randall
RL
. 
Prospects for targeted therapy of synovial sarcoma
.
J Pediatr Hematol Oncol
2005
;
27
:
219
22
.
18.
Yang
JL
,
Hannan
MT
,
Russell
PJ
,
Crowe
PJ
. 
Expression of HER1/EGFR protein in human soft tissue sarcomas
.
Eur J Surg Oncol
2006
;
32
:
466
8
.
19.
Tschoep
K
,
Kohlmann
A
,
Schlemmer
M
,
Haferlach
T
,
Issels
RD
. 
Gene expression profiling in sarcomas
.
Crit Rev Oncol Hematol
2007
;
63
:
111
24
.
20.
Benassi
MS
,
Ponticelli
F
,
Azzoni
E
,
Gamberi
G
,
Pazzaglia
L
,
Chiechi
A
, et al
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas
.
Histol Histopathol
2007
;
22
:
1017
24
.
21.
Mazar
AP
,
Ahn
RW
,
O'Halloran
TV
. 
Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic
.
Curr Pharm Des
2011
;
17
:
1970
8
.
22.
Schappa
JT
,
Frantz
AM
,
Gorden
BH
,
Dickerson
EB
,
Vallera
DA
,
Modiano
JF
. 
Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors
.
Int J Cancer
2013
;
133
:
1936
44
.
23.
Waldron
NN
,
Oh
S
,
Vallera
DA
. 
Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma
.
Oral Oncol
2012
;
48
:
1202
7
.
24.
Gorden
BH
,
Kim
JH
,
Sarver
AL
,
Frantz
AM
,
Breen
M
,
Lindblad-Toh
K
, et al
Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization
.
Am J Pathol
2014
;
184
:
985
95
.
25.
Tonomura
N
,
Elvers
I
,
Thomas
R
,
Megquier
K
,
Turner-Maier
J
,
Howald
C
, et al
Genome-wide association study identifies shared risk loci common to two malignancies in golden retrievers
.
PLoS Genet
2015
;
11
:
e1004922
.
26.
Temiz
NA
,
Moriarity
BS
,
Wolf
NK
,
Riordan
JD
,
Dupuy
AJ
,
Largaespada
DA
, et al
RNA sequencing of Sleeping Beauty transposon-induced tumors detects transposon-RNA fusions in forward genetic cancer screens
.
Genome Res
2016
;
26
:
119
29
.
27.
Sarver
AE
,
Sarver
AL
,
Thayanithy
V
,
Subramanian
S
. 
Identification, by systematic RNA sequencing, of novel candidate biomarkers and therapeutic targets in human soft tissue tumors
.
Lab Invest
2015
;
95
:
1077
88
.
28.
Charbonneau
B
,
Vogel
RI
,
Manivel
JC
,
Rizzardi
A
,
Schmechel
SC
,
Ognjanovic
S
, et al
Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma
.
Hum Pathol
2013
;
44
:
1918
26
.
29.
Tamburini
BA
,
Trapp
S
,
Phang
TL
,
Schappa
JT
,
Hunter
LE
,
Modiano
JF
. 
Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed
.
PLoS One
2009
;
4
:
e5549
.
30.
Li
L
,
Sarver
AL
,
Alamgir
S
,
Subramanian
S
. 
Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma
.
Lab Invest
2012
;
92
:
571
83
.
31.
Huang
X
,
Park
H
,
Greene
J
,
Pao
J
,
Mulvey
E
,
Zhou
SX
, et al
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas
.
PLoS One
2015
;
10
:
e0133152
.
32.
Scott
MC
,
Sarver
AL
,
Tomiyasu
H
,
Cornax
I
,
Van Etten
J
,
Varshney
J
, et al
Aberrant retinoblastoma (RB)-E2F transcriptional regulation defines molecular phenotypes of osteosarcoma
.
J Biol Chem
2015
;
290
:
28070
83
.
33.
Koopmeiners
JS
,
Modiano
J
. 
A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes
.
Clin Trials
2014
;
11
:
38
48
.
34.
Vail
DM
. 
Veterinary co-operative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0
.
Vet Comp Oncol
2004
;
2
:
195
213
.
35.
Hinchcliff
KW
,
DiBartola
SP
. 
Quality matters: publishing in the era of CONSORT, REFLECT, and EBM
.
J Vet Intern Med
2010
;
24
:
8
9
.
36.
R Core Team
. 
R: a language and environment for statistical computing
.
Vienna
,
Austria
:
R Foundation for Statistical Computing
; 
2013
.
37.
Stish
BJ
,
Oh
S
,
Chen
H
,
Dudek
AZ
,
Kratzke
RA
,
Vallera
DA
. 
Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
.
Br J Cancer
2009
;
101
:
1114
23
.
38.
Oh
S
,
Stish
BJ
,
Sachdev
D
,
Chen
H
,
Dudek
AZ
,
Vallera
DA
. 
A novel “reduced immunogenicity” bispecific targeted toxin simultaneously recognizing human EGF and IL-4 receptors in a mouse model of metastatic breast carcinoma
.
Clin Cancer Res
2009
;
15
:
6137
47
.
39.
Pai
LH
,
Wittes
R
,
Setser
A
,
Willingham
MC
,
Pastan
I
. 
Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin
.
Nat Med
1996
;
2
:
350
3
40.
Bachanova
V
,
Frankel
AE
,
Cao
Q
,
Lewis
D
,
Grzywacz
B
,
Verneris
MR
, et al
Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies
.
Clin Cancer Res
2015
;
21
:
1267
72
.
41.
Smallshaw
JE
,
Ghetie
V
,
Rizo
J
,
Fulmer
JR
,
Trahan
LL
,
Ghetie
MA
, et al
Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice
.
Nat Biotechnol
2003
;
21
:
387
91
.
42.
Onda
M
,
Nagata
S
,
FitzGerald
DJ
,
Beers
R
,
Fisher
RJ
,
Vincent
JJ
, et al
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients
.
J Immunol
2006
;
177
:
8822
34
.
43.
Frankel
AE
,
Woo
JH
,
Ahn
C
,
Foss
FM
,
Duvic
M
,
Neville
PH
, et al
Resimmune, an anti-CD3ϵ recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma
.
Haematologica
2015
;
100
:
794
800
.
44.
Thamm
DH
. 
Miscellaneous tumors
. In:
Withrow
SJ
,
Vail
DM
,
Page
RL
,
editors
.
Withrow and MacEwen's small animal clinical oncology
. 5th ed.
St. Louis, MO
:
Elsevier
; 
2013
. p.
679
688
.
45.
Clifford
CA
,
Mackin
AJ
,
Henry
CJ
. 
Treatment of canine hemangiosarcoma: 2000 and beyond
.
J Vet Intern Med
2000
;
14
:
479
85
.
46.
Lana
S
,
U'Ren
L
,
Plaza
S
,
Elmslie
R
,
Gustafson
D
,
Morley
P
, et al
Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs
.
J Vet Intern Med
2007
;
21
:
764
9
.
47.
U'Ren
LW
,
Biller
BJ
,
Elmslie
RE
,
Thamm
DH
,
Dow
SW
. 
Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma
.
J Vet Intern Med
2007
;
21
:
113
20
.
48.
Vail
DM
,
MacEwen
EG
,
Kurzman
ID
,
Dubielziq
RR
,
Helfand
SC
,
Kisseberth
WC
, et al
Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial
.
Clin Cancer Res
1995
;
1
:
1165
70
.
49.
Kreitman
RJ
,
Tallman
MS
,
Robak
T
,
Coutre
S
,
Wilson
WH
,
Stetler-Stevenson
M
, et al
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
.
J Clin Oncol
2012
;
30
:
1822
8
.
50.
Anwar
S
,
Yanai
T
,
Sakai
H
. 
Immunohistochemical detection of urokinase plasminogen activator and urokinase plasminogen activator receptor in canine vascular endothelial tumours
.
J Comp Pathol
2015
;
153
:
278
82
.
51.
Kim
JH
,
Frantz
AM
,
Anderson
KL
,
Graef
AJ
,
Scott
MC
,
Robinson
S
, et al
Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment
.
Exp Cell Res
2014
;
323
:
155
64
.
52.
Tamburini
BA
,
Phang
TL
,
Fosmire
SP
,
Scott
MC
,
Trapp
SC
,
Duckett
MM
, et al
Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma
.
BMC Cancer
2010
;
10
:
619
.